Suggested remit: To appraise the clinical and cost effectiveness of empagliflozin within its marketing authorisation for treating chronic heart failure with reduced ejection fraction.
 
Status In progress
Process STA 2018
ID number 3826

Provisional Schedule

Expected publication 02 February 2022

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Boehringer Ingelheim (empagliflozin)
Others Department of Health and Social Care
  NHS Bracknell and Ascot CCG
  NHS England
  NHS Slough CCG
  Welsh Government
Patient carer groups Arrhythmia Alliance
  Atrial Fibrillation Association
  Blood Pressure UK
  British Cardiac Patients Association
  Cardiomyopathy UK
  Cardiovascular Care Partnership
  CRY (Cardiac Risk in the Young)
  HEART UK
  Network of Sikh Organisations
  Pumping Marvellous Foundation
  Somerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association for Nursing in Cardiovascular Care
  British Cardiovascular Society
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Nuclear Cardiology Society
  British Society for Heart Failure
  British Society of Cardiovascular Imaging
  National Heart and Lung Institute
  Primary Care Cardiovascular Society
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Society of Medicine
  Society for Cardiological Science & Technology
  Society for Vascular Nurses
  Society for Vascular Technology
  UK Clinical Pharmacy Association
  Vascular Society of Great Britain and Ireland

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies A. Menarini Farmaceutica Internazionale SRL (nebivolol)
  Accord (bisoprolol, captopril, enalapril, eplerenone, , irbesartan, , lisinopril, losartan, nebivolol, olmesartan, perindopril, ramipril, spironolactone, telmisartan, valsartan)
  Advanz (nebivolol)
  Aspire (eplerenone)
  AstraZeneca (dapagliflozin, lisinopril)
  Aurobindo Pharma (bisoprolol, candesartan, carvedilol, enalapril, irbesartan, lisinopril, losartan, nebivolol, olmesartan, perindopril, quinapril, ramipril, valsartan)
  Boehringer Ingelheim (telmisartan)
  Brown and Burk (irbesartan, lisinopril, losartan, ramipril)
  Consilient Health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan)
  Daiichi Sankyo (olmesartan)
  Dexcel Pharma (enalapril, losartan, valsartan)
  Flamingo pharma (bisoprolol)
  Glenmark Pharma (nebivolol, olmesartan, perindopril, telmisartan)
  Lupin Healthcare (irbesartan, quinapril)
  Martindale pharma (captopril)
  Merck Sharp & Dohme (bisoprolol, enalapril, losartan)
  Mylan (bisoprolol, candesartan, enalapril, eplerenone, eprosartan, lisinopril, losartan, olmesartan, perindopril, valsartan)
  Novartis (sacubitril valsartan, valsartan)
  Pfizer (eplerenone, quinapril, spironolactone)
  Rosemont pharmaceuticals (ramipril)
  Sandoz (bisoprolol, candesartan, losartan, ramipril)
  Sanofi (irbesartan, ramipril, spironolactone)
  Servier laboratories (arginine, perindopril)
  Takeda (azilsartan, candesartan)
  Ten pharma (captopril)
  Thame Laboratories (captopril)
  Thornton and Ross (olmesartan)
  Tillomed laboratories (eplerenone, perindopril)
  Wockhardt (ramipril)
  Zentiva (eplerenone, irbesartan, ramipril)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Dept, Barts
  Circulation Foundation
  Cochrane Heart Group
  Cochrane Vascular
  European Council for Cardiovascular Research
  Genomics England
  Heart Research UK
  MRC Clinical Trials Unit
  National Centre for Cardiovascular Preventions and Outcomes
  National Institute for Health Research
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
12 March 2021 Invitation to participate
12 March 2021 In progress
28 January 2021 - 25 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance